Next Article in Journal / Special Issue
Complications from Surgeries Related to Ovarian Cancer Screening
Previous Article in Journal / Special Issue
Psychological and Behavioral Impact of Participation in Ovarian Cancer Screening
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessOpinion
Diagnostics 2017, 7(1), 14; doi:10.3390/diagnostics7010014

A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology and the Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40515, USA
Academic Editor: Andreas Kjaer
Received: 7 January 2017 / Revised: 15 February 2017 / Accepted: 23 February 2017 / Published: 8 March 2017
(This article belongs to the Special Issue Ovarian Cancer Screening)
View Full-Text   |   Download PDF [495 KB, uploaded 8 March 2017]   |  

Abstract

The history of biomarkers and ultrasonography dates back over more than 50 years. The present status of biomarkers used in the context of ovarian cancer is addressed. Attention is given to new interpretations of the etiology of ovarian cancer. Cancer antigen 125 (CA125) and multivariate index assays (Ova1, Risk of Ovarian Malignancy Algorithm, Overa) are biomarker-driven considerations that are presented. Integration of biomarkers into ovarian cancer diagnostics and screening are presented in conjunction with ultrasound. Consideration is given to the serial application of both biomarkers and ultrasound, as well as morphology-based indices. Attempts are made to foresee how individualized molecular signatures may be able to both provide an alert of the potential for ovarian cancer and to provide molecular treatments tailored to a personalized genetic signature. In the future, an annual pelvic ultrasound and a comprehensive serum biomarker screening/diagnostic panel may replace the much maligned bimanual examination as part of the annual gynecologic examination. Taken together, it is likely that a new medical specialty for screening and early diagnostics will emerge for physicians and epidemiologists, a field of study that is independent of patient gender, organ, or the subspecialties of today. View Full-Text
Keywords: biomarkers; ovarian tumor biomarkers; ultrasound; serial ultrasound; ovarian cancer biomarkers; ovarian tumor biomarkers; ultrasound; serial ultrasound; ovarian cancer
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ueland, F.R. A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come. Diagnostics 2017, 7, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top